#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt